$VBIO
Valion Bio, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · San Antonio, TX
VBIO chart
What traders are saying about $VBIO
Latest postsValion Bio, Inc. news
- Valion Bio Announces Series B Preferred Stock Financing
TipRanks ·
- Valion Bio Raises $700,000 From 3i in Series B Preferred Stock and Warrant Sale
TradingView ·
- Valion Bio, Inc. (VBIO) Seasonal returns chart
Yahoo Finance UK ·
- Radiation Countermeasure Entolimod Clears Mouse Safety Study, Moves to Survival Test
Global Biodefense ·
- Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
Yahoo Finance ·
- Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation
Yahoo Finance ·
- Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
Yahoo Finance ·
- Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
Yahoo Finance ·
- Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
Yahoo Finance ·
- With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
Yahoo Finance ·
- Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Yahoo Finance ·
- New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
Yahoo Finance ·
Valion Bio, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $780,000 | $1.2M | $1.8M |
| Net income | -$8.9M | -$5.7M | -$8.2M | -$10.1M |
| Diluted EPS | – | $-19.68 | $-176.80 | $-104.32 |
| Total assets (year end) | $31.6M | $2.8M | $5.2M | $5.9M |
| Cash and equivalents (year end) | $12.6M | $2.0M | $3.4M | $3.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 8-KCURRENT REPORT
- 8-KFORM 8-K
- 8-KFORM 8-K
- 8-KFORM 8-K
- 8-KFORM 8-K
- 8-KFORM 8-K
- 8-KFORM 8-K
- DEF 14ADEFINITIVE PROXY STATEMENT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KFORM 8-K
About Valion Bio, Inc.
- Ticker
- VBIO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Antonio, TX
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1787740
- Former names
- Tivic Health Systems, Inc.
Frequently asked questions
What exchange is Valion Bio, Inc. listed on?
Valion Bio, Inc. trades on the Nasdaq under the ticker symbol VBIO.
What industry is Valion Bio, Inc. in?
Valion Bio, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Valion Bio, Inc. headquartered?
Valion Bio, Inc.'s business address on file with the SEC is in San Antonio, TX.
When does Valion Bio, Inc.'s fiscal year end?
Valion Bio, Inc.'s fiscal year ends on December 31.
How much revenue did Valion Bio, Inc. report?
Valion Bio, Inc. reported $780,000 in revenue for calendar year 2024, according to its SEC filings.